Search Results
Jul 19, 2026, 18:43 ET Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
PolyPeptide Group AG ("PolyPeptide") (ISIN CH1110760852, ticker symbol: PPGN), a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs).
More news about: Samsung Biologics
Jul 17, 2026, 00:06 ET 啟新生技依循PIC/S GMP規範 打造細胞治療原物料與製造平台，瞄準日本、新加坡市場
GMP轉換、技術移轉、無菌充填及品質檢測，協助客戶加速從研發走向臨床應用。配合亞洲生技大展帶動的國際交流，啟新於7月14日接待僑務委員會主辦的「2026年臺灣生物科技產業參訪團」。21位來自四大洲、10個國家的僑臺商與企業主，實地走訪細胞培養基生產線與產品展示空間，了解啟新在再生醫療關鍵原料、細胞培養、製程開發及品質檢測的服務量能。團員背景涵蓋全球藥廠、CDMO、基因工程及生醫投資等領域，包括全球RNAi療法領導廠商Alnylam的CMC產品開發主管，以及英國阿斯特捷利康（AstraZeneca）全球法規事務總監等企業代表。啟新2025年底已與新加坡ESCO簽署合作協議，逐步建立東南亞市場合作基礎，未來將持續拓展
More news about: 啟新生物科技
Jul 14, 2026, 20:00 ET Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet
More news about: Insilico Medicine
Jul 14, 2026, 07:45 ET Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
timing and supply-chain readiness while creating the potential to support future government procurement, internal development programs and third-party CDMO services.Oncology expansion: The biological activity of the TLR5 platform may support development opportunities beyond biodefense, including
More news about: Valion Bio, Inc.
Jul 09, 2026, 03:31 ET WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
please visit: www.wuxibiologics.com.*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)*The winner of the "2026 Best Contract Development & Manufacturing Organization
More news about: WuXi Biologics
Jul 08, 2026, 10:00 ET Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced that its application for segmented production of antibody-drug conjugates (ADCs) at its Hangzhou site successfully passed a comprehensive
More news about: Altruist Biologics
Jul 08, 2026, 10:00 ET Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production
2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced that its application for segmented production of antibody-drug conjugates (ADCs) at its Hangzhou site successfully passed a comprehensive
More news about: Altruist Biologics
Jul 08, 2026, 09:38 ET Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton AdvancedPorton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has dual-headquarters in Cranbury, New Jersey, and Suzhou, China, providing end-to-end CDMO solutions for ATMPs including plasmids, viral vectors, cell therapy and nucleic acid
More news about: Porton Advanced
Jul 08, 2026, 09:22 ET Cambrex、Snapdragon Chemistry 及 Q1 Scientific 憑藉製藥業創新與可持續發展成果獲肯定
新澤西州東拉瑟福德2026年7月8日 /美通社/ -- 全球領先的合約開發及製造機構 (CDMO) Cambrex 欣然宣佈，旗下公司 Snapdragon Chemistry 與 NewAmsterdam Pharma 獲頒美國化學學會 2026 年綠色化學挑戰獎 (American Chemical Society's 2026 Green Chemistry Challenge Award)，以表彰其在藥物合成方面開發出更環保的合成途徑。
More news about: Cambrex
Jul 08, 2026, 09:00 ET Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
AdvancedPorton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical
More news about: Porton Advanced
Jul 08, 2026, 08:00 ET Evonik invests US$100 million to upgrade its U.S. drug substance contract manufacturing site
footprint across North America, Europe, and Asia, with a strategic emphasis on North America for its Drug Substance CDMO business. Evonik's Tippecanoe site is a cornerstone of the company's global CDMO network for small-molecule drug substances. The modernization at the Tippecanoe site is an investment into Next
More news about: Evonik Industries AG
Jul 08, 2026, 08:00 ET Evonik investiert 100 Millionen US-Dollar in die Auftragsfertigung moderner pharmazeutischer Wirkstoffe in Lafayette, USA
Investition ist es, Automatisierung, Ergonomie und Effizienz deutlich zu erhöhen und sich als Dienstleister für die Auftragsentwicklung und Auftragsfertigung (CDMO) für Pharmakunden in den USA noch besser aufzustellen. Die Investition wird auf regionaler Ebene gefördert.
More news about: Evonik Industries AG
Jul 08, 2026, 08:00 ET Evonik invests US$100 million to upgrade drug substance manufacturing site in Lafayette, Indiana
across North America, Europe, and Asia, with a particular emphasis on North America for its drug substance CDMO business. Evonik's Tippecanoe site is a bedrock of the company's global CDMO network for small-molecule drug substances. Small molecules have been a cornerstone of medicine for decades
More news about: Evonik Industries AG
Jul 08, 2026, 07:44 ET Il rapporto annuale di Piramal Pharma per l'esercizio finanziario 2026 mette in evidenza la portata globale dell'azienda, la sua crescita spinta dall'innovazione e i traguardi raggiunti in materia di sostenibilità
salienti del rapporto:Piramal Pharma Solutions (CDMO), che ha contribuito per il 55% al fatturato della società, ha continuato a rafforzare la propria posizione di leader globale nel settore CDMO integrato, assistendo oltre 500 clienti in tutto il mondo nell'ecosistema
More news about: Piramal Pharma Limited
Jul 08, 2026, 07:20 ET Cambrex, Snapdragon Chemistry e Q1 Scientific são reconhecidas por sua inovação e sustentabilidade no setor farmacêutico
8 de julho de 2026 /PRNewswire/ -- A Cambrex, organização líder global em desenvolvimento e fabricação por contrato (CDMO), anuncia com orgulho que a Snapdragon Chemistry, uma empresa da Cambrex, junto com a NewAmsterdam Pharma, recebeu o Prêmio Desafio de Química Verde
More news about: Cambrex
Jul 08, 2026, 07:16 ET Cambrex, Snapdragon Chemistry y Q1 Scientific son reconocidos por su innovación y sostenibilidad en el sector farmacéutico
8 de julio de 2026 /PRNewswire/ -- Cambrex, una empresa líder mundial en desarrollo y fabricación por contrato (CDMO, por sus siglas en inglés), anuncia con orgullo que Snapdragon Chemistry, una empresa de Cambrex, junto con NewAmsterdam Pharma, ha recibido el Premio
More news about: Cambrex
Jul 08, 2026, 03:15 ET WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
please visit: www.wuxibiologics.com.*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)*The winner of the "2026 Best Contract Development & Manufacturing Organization
More news about: WuXi Biologics
Jul 08, 2026, 02:54 ET Der Geschäftsbericht von Piramal Pharma für das Geschäftsjahr 2026 unterstreicht die globale Reichweite, das innovationsgetriebene Wachstum und die Meilensteine im Bereich Nachhaltigkeit
Wichtige Highlights aus dem Bericht: Piramal Pharma Solutions (CDMO), das 55 % des Umsatzes des Unternehmens ausmachte, baute seine Position als führender integrierter globaler CDMO weiter aus und unterstützte über 500 globale Kunden im gesamten Pharma- und Biotechnologie-Ökosystem.
More news about: Piramal Pharma Limited
Jul 08, 2026, 00:29 ET Le rapport annuel de Piramal Pharma pour l'exercice 2026 souligne l'envergure mondiale de la société, sa croissance axée sur l'innovation et ses avancées majeures en matière de développement durable
visibilité sur notre croissance future. »Principaux points à retenir du rapport :Piramal Pharma Solutions (CDMO), qui représente 55 % du chiffre d'affaires de la société, a consolidé sa position d'acteur mondial de premier plan dans le domaine des services
More news about: Piramal Pharma Limited
Jul 08, 2026, 00:20 ET El informe anual de Piramal Pharma del año fiscal 2026 destaca su alcance global
futuro".Aspectos destacados del informe: Piramal Pharma Solutions (CDMO), que aportó el 55% de los ingresos de la Compañía, continuó fortaleciendo su posición como una CDMO global integrada líder, brindando soporte a más de 500 clientes globales en todo el ecosistema
More news about: Piramal Pharma Limited
Jul 07, 2026, 15:49 ET Cambrex, Snapdragon Chemistry y Q1 Scientific: innovación y sostenibilidad en el sector farmacéutico
7 de julio de 2026 /PRNewswire/ -- Cambrex, organización líder mundial en desarrollo y fabricación por contrato (CDMO), se enorgullece al anunciar que Snapdragon Chemistry, una empresa de Cambrex, junto con NewAmsterdam Pharma, ha conseguido el Premio Desafío de Química
More news about: Cambrex
Jul 07, 2026, 15:41 ET Cambrex, Snapdragon Chemistry et Q1 Scientific sont reconnus pour leur innovation et leur durabilité dans le secteur pharmaceutique
7 juillet 2026 /PRNewswire/ -- Cambrex, l'un des principaux organismes de développement et de fabrication sous contrat (CDMO) au niveau mondial, est fier d'annoncer que Snapdragon Chemistry, une société du groupe Cambrex, en collaboration avec NewAmsterdam Pharma, a reçu le
More news about: Cambrex
Jul 07, 2026, 09:00 ET Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene therapy, MCO-010
limited therapeutic options.About Catalent Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture, and launch reflects
More news about: Nanoscope Therapeutics
Jul 07, 2026, 08:50 ET Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
growth."Key Highlights from the report:Piramal Pharma Solutions (CDMO), which contributed 55% of the Company's revenue, continued to strengthen its position as a leading integrated global CDMO, supporting over 500 global customers across the pharmaceutical and biotechnology
More news about: Piramal Pharma Limited
Jul 07, 2026, 08:36 ET Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
growth."Key Highlights from the report:Piramal Pharma Solutions (CDMO), which contributed 55% of the Company's revenue, continued to strengthen its position as a leading integrated global CDMO, supporting over 500 global customers across the pharmaceutical and biotechnology
More news about: Piramal Pharma Limited